Evidence for a Potential Role of Metallothioneins in Inflammatory Bowel Diseases by Waeytens, Anouk et al.
Hindawi Publishing Corporation
Mediators of Inﬂammation
Volume 2009, Article ID 729172, 9 pages
doi:10.1155/2009/729172
Review Article
Evidencefor a Potential Role of Metallothioneinsin
InﬂammatoryBowelDiseases
Anouk Waeytens,MartineDe Vos, andDebbyLaukens
Department of Gastroenterology, Ghent University, De Pintelaan 185, 9000 Gent, Belgium
Correspondence should be addressed to Anouk Waeytens, anouk.waeytens@ugent.be
Received 26 January 2009; Accepted 3 July 2009
Recommended by Donna-Marie McCaﬀerty
Inﬂammatory bowel diseases (IBDs) are a group of chronic, relapsing, immune-mediated disorders of the intestine, including
Crohn’s disease and ulcerative colitis. Recent studies underscore the importance of the damaged epithelial barrier and the
dysregulated innate immune system in their pathogenesis. Metallothioneins (MTs) are a family of small proteins with a high and
conserved cysteine content that are rapidly upregulated in response to an inﬂammatory stimulus. Herein, we review the current
knowledge regarding the expression and potential role of MTs in IBD. MTs exert a central position in zinc homeostasis, modulate
the activation of the transcription factor nuclear factor (NF)-κB, and serve as antioxidants. In addition, MTs could be involved in
IBD through their antiapoptotic eﬀects or through speciﬁc immunomodulating extracellular eﬀects. Reports on MT expression in
IBD are contradictory but clearly demonstrate a deviant MT expression supporting the idea that these aberrations in IBD require
further clariﬁcation.
Copyright © 2009 Anouk Waeytens et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Metallothioneins (MTs) are a superfamily of small proteins
that are present in virtually every living organism [1].
A typical feature is their highly conserved number and
position of cysteine residues, enabling them to incorporate
monovalent and divalent metal atoms and to reduce reactive
oxygen and nitrogen species [2]. So far, 19 human isoforms
have been cloned, 11 of which are known to be functional
(i.e., MT1A, MT1B, MT1E, MT1F, MT1G, MT1H, MT1M,
MT1X, MT2A, MT3, and MT4) [3]. The majority of these
genes cluster together on a single locus on chromosome
16 (16q13) [4]. Heterogeneity of isoforms results from
posttranslational modiﬁcations and/or variations in metal
composition [5]. The most widely expressed isoforms are
MT-1 and MT-2, and they are highly inducible [3]. On the
basal level, MT-2 appears to be expressed more than the MT-
1 isoforms. The MT-3 and MT-4 proteins are constitutively
expressed and are found mainly in the brain [6], kidney [7],
andreproductiveorgans[8](MT -3)andincertainsquamous
epithelia [9] (MT-4). Human MT isoforms are regulated
independently of each other and can be induced by metals,
stress hormones, cytokines, reactive oxygen species (ROS),
and chemicals [3]. In mice, the situation is more simple.
Only four functional murine MT genes are known (MT1,
MT2, MT3, and MT4), and the MT1 and MT2 isoforms are
coordinately regulated [5, 10].
2. MT Regulation in Inﬂammation
One of the most striking observations that link MTs
to inﬂammation is their rapid upregulation in response
to a variety of stresses including inﬂammation. Hepatic
expression of MTs is dramatically elevated in response
to bacterial infection, an eﬀect mediated by endotoxin
(lipopolysaccharide-LPS). This observation has lead to the
classiﬁcation of MTs as acute phase proteins. LPS induction
of MT gene expression in mice occurred in each organ
examined (liver, kidney, pancreas, intestine, lung, heart,
brain, ovary, uterus, and spleen) [11]. This induction by
LPS was shown to be mediated by several proinﬂammatory
cytokines, including interleukin (IL)-1, IL-6, tumor necrosis
factor (TNF)-α, interferon (IFN)-γ [11], nitric oxide (NO)2 Mediators of Inﬂammation
[12] as well as the stress hormones glucocorticoids [13].
These factors have been shown to be able to upregulate
MTs independently of LPS. They seem to act synergistically
and result in diﬀerent levels of MT expression, depending
on the tissue and the combination of factors [11, 14–16].
ROS generated during the inﬂammatory response may acti-
vate MT expression through multiple pathways, including
directly by stimulating an antioxidant response element and
speciﬁc metal response elements in the promoter region as
wellasindirectlybyeventsassociatedwithsecond-messenger
protein kinase pathways [17, 18]. During radiation injury
to the small intestine, which implicates ROS and leads to
acute inﬂammation, metallothioneins were induced [19]. All
these data illustrate that MT regulation in inﬂammation is a
rapid but complex process with diﬀerent results in diﬀerent
tissues. One constant, however, is that MT induction by
inﬂammatory mediators seems to be conditional upon the
presence of zinc [5].
3. MT FunctionsRelevant in
Inﬂammation and Possibly in Inﬂammatory
BowelDiseases(Figure1)
The ﬁrst function of MTs that was put forward as playing a
roleininﬂammationwastheircentralpositioninzinchome-
ostasis, redistributing the intracellular zinc pool. In that way,
MTs can have two opposite roles: they can either increase
the intracellular zinc pool, thereby facilitating metabolic
processes during the acute phase response or sequester
zinc to allow maximal activity of enzymes which would be
otherwise inhibited by zinc [5]. Clarifying these postulations
is hampered by the immense number of enzymes that use
or are inhibited by zinc. Furthermore, the aﬃnity of MTs
for zinc probably diﬀers depending on the stimulus by
which MTs are induced. In an in vivo displacement assay
of cadmium (whose aﬃnity for MT is stronger than that
of zinc), it was shown that oxidative stress-induced MT
displaced zinc to cadmium, on the other hand, MT induced
by fasting stress or by restraint stress did not [20]. This study
did not make a distinction between diﬀerent MT isoforms,
although metal-binding capacities of isoforms can vary [21,
22], as can their gene-regulation [23, 24]. Conformational
changes of MT under certain stimuli might also explain the
observedinﬂuenceonzincaﬃnity.Ithasbeenshownthatthe
binding of ATP (which reﬂects the energy state of a cell) to
MTelicitedconformationalchangesandalteredzincbinding
in MT [25].
Zinc deﬁciency is a potential complication of Crohn’s
disease and may result from a variety of processes, includ-
ing reduced dietary intake, impaired absorption, increased
excretion, hypoalbuminemia, or an internal redistribution of
zinc [26, 27]. Although the consequences of this deﬁciency
on the pathogenesis of the disease are not clear [28], it
could be implicated through the involvement of zinc in
immune function, redox signalling, and wound healing [29–
32]. Zinc is crucial for the normal development and function
of cells mediating innate immunity, that is, neutrophils,
macrophages, and natural killer cells [33]. Phagocytosis,
intracellular killing, chemotaxis, and oxidative burst are all
negatively aﬀected by zinc deﬁciency. In Crohn’s disease,
a defective innate immune response is more and more
accepted as a pathogenic mechanism [34]. Zinc also has
antiinﬂammatory properties. An important target herein is
nuclear factor (NF)-κB, a transcription factor that has a
pivotal role in immune and inﬂammatory responses and as
such also in IBD. Eﬀects of zinc on NF-κBa c t i v i t yh a v e
been attributed to its inﬂuence on the expression of the zinc-
ﬁnger protein A20 that sequesters NF-κB in the cytoplasm
and inhibits IL-1- and TNF-α-induced activation of NF-κB
[35]. In vitro, zinc enhances the upregulation of A-20, thus
decreasing NF-κB activation and leading to decreased gene
expression and generation of TNF-α,I L - 1 β, and IL-8 [36].
Takingtheseﬁndingsintoaccount,alackofintracellularzinc
ionbioavailabilitymayhampertheinhibitionofNF-κB, with
subsequent maintenance of chronic inﬂammation.
The gene expression of IL-2, IL-12, and IFN-γ (T helper
type 1 or Th1 cytokines) is zinc dependent, whereas T helper
type 2 (Th2) cytokines in general are not aﬀected by zinc
deﬁciency [33]. As a consequence, an imbalance of Th1/Th2
cytokines appears in an experimental model of human zinc
deﬁciencywithadecreaseofTh1cytokinesandashifttoward
aT h 2p h e n o t y p e[ 37]. This observation stands in contrast
with the excessive Th1 cell response in the inﬂamed mucosa
of Crohn’s disease patients with active disease. However, in
Crohn’s disease patients with inactive disease, hyposecretion
of IFN-γ is reported [38, 39]. Even though a relationship
with zinc status has not been examined in these studies, zinc
deﬁciency could be at the basis of this observation.
Studies where zinc was administered to rats or mice
with chemically induced colitis showed a dose-dependent
therapeutic eﬀect [40–44]. Furthermore, zinc was shown
to induce MT synthesis in ileal and colonic mucosa of
control rats and to a lesser extent in that of colitic rats
[45]. A placebo-controlled double-blind cross-over trial was
conducted with seven Crohn’s disease patients and seven
ulcerative colitis patients that had inactive to moderately
active disease and received oral zinc supplementation [46].
Althoughsupplementationincreasedplasmazincconcentra-
tions and slightly (but not signiﬁcantly) increased mucosal
MT concentration, there were no changes in histological
inﬂammation or disease activity. However, it seems that
zinc supplementation can resolve permeability alterations
in patients with Crohn’s disease in remission and as such
reduce the risk of relapse in Crohn’s disease [47]. This
observationissupportedbydatathatshowapositiveeﬀectof
exogenouszinconintestinalrepairinvitro[30]andontight-
junction permeability in experimental colitis [42]. Although
the precise mechanism is not understood, it appears to be
independent of MTs [48].
Next to their role in zinc homeostasis, MTs are reported
to modulate the activation of NF-κB. However, published
results vary concerning the relationship between MT expres-
sion level and NF-κBa c t i v i t y .T h em o d u l a t o r ye ﬀect might
be based upon a direct interaction [49], regulation of zinc
concentrations [50], or modulation of the redox balance
through antioxidant functions [51]. Data supporting a pos-
itive regulatory role for MTs on NF-κB activity are the zinc-
induced inhibition of this activity. Through sequestrationMediators of Inﬂammation 3
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Figure 1: MT functions relevant in IBD. IBD is characterized by the presence of an increased level of ROS in the mucosal intestinal tissue as
well as oxidative DNA and protein damage, defective host-microbe interactions, immune cell inﬁltration, and a disturbed T cell apoptosis.
Onalloftheseelements,MTscanhaveeﬀects.Inaddition,MTscanhaveadualroleinenzymeactivationthroughthereleaseorsequestration
ofzinc.Finally,MTsarereportedtoregulatetheactivationofthetranscriptionfactorNF-κB,whichhasakeyroleininﬂammatoryresponses.
of zinc, MTs can attenuate this zinc-induced inhibition
and activate NF-κB[ 50]. The requirement of MTs for
the expression of macrophage colony stimulating factor, a
chemokine downstream of NF-κB, is another illustration of
this positive regulatory role [52]. On the other hand, data
existthatMTsmayfunctionasanegativeregulatorofNF-κB,
showing that MTs inhibited the activation of NF-κBb yT N F -
α [53, 54] and that splenocytes from MTnull mice displayed
elevated levels of NF-κBa c t i vi ty[ 55]. Although these reports
seem contradictory, explanations for this discrepancy could
be found in the distinct redox regulation of NF-κBa c t i v a t i o n
between the cytoplasm and the nucleus [51], a balance
which may be modulated by the antioxidant capacities of
MTs. Another explanation might be found in diﬀerences
in the cell types used. Although it seems obvious that a
(negative or positive) correlation exists, MT eﬀects can also
be independent of NF-κB. For example, a protective eﬀect of
MTs on acute inﬂammatory lung injury was not mediated
via NF-κB dependent pathways [56]. Thus, to determine
the exact role of MTs in the NF-κBp a t h w a yi nI B D ,N F -
κB activity should be investigated in vivo in experimental
models.
As just mentioned, the antioxidant capacities of MTs
might inﬂuence the inﬂammatory response through mod-
ulating NF-κB activity, but a more obvious role for MTs
as antioxidants is the sequestration of harmful oxygen
and nitrogen intermediates which are generated during
the inﬂammatory response. In order to kill bacteria and
parasites, inﬁltrating neutrophils and macrophages produce
freeoxygenradicals(hydrogenperoxide,NO,andsuperoxide
anion) which are extremely cytotoxic to host cells [57, 58].
MTs can, together with other known molecules such as
superoxide dismutase, vitamin E, and ascorbate, provide a
cytoprotection for host cells, preventing cellular damage and
allowing survival and growth in an inﬂammatory environ-
ment [59]. The increased presence of ROS, an imbalance
in antioxidant expression, and oxidative DNA and protein
damage have been reported in IBD [60–63]. In Crohn’s
disease, oxidative damage as measured by lipid peroxidation
correlated inversely with the concentration of MTs [61]. ROS
can disrupt the epithelial barrier function by destabilizing
tight junctions [64], thus increasing permeability, a phe-
nomenon which is observed in patients with Crohn’s disease
[65]. Experiments in animal models of IBD have already
conﬁrmed the possibility to use antioxidants as therapeutic
agents [66–69]. In IL-10 deﬁcient mice, local mucosal
administration of the antioxidant enzyme superoxide dis-
mutase (SOD) by genetically modiﬁed Lactobacillus bacteria
signiﬁcantly reduced the severity of inﬂammation [70].
Mice overexpressing human SOD demonstrated attenuated
inﬂammation when subjected to a mild form of dextran
sodium sulphate- (DSS-) induced colitis and a remarkable
survival beneﬁt from severe DSS colitis [71].
In certain oxidative and inﬂammatory environments
MTs have been shown to reduce apoptosis [72], and in
cases where inﬂammation-dependent apoptosis is detri-
mental, induction of MTs might provide a beneﬁt. Since
Crohn’s disease is characterized by defective T cell apoptosis,
whereas T cells from ulcerative colitis patients show a strong
activation induced apoptosis, the role of MTs might be
diﬀerent in these two diseases. MTs have also been accredited
antimicrobial properties [73, 74], which might be another4 Mediators of Inﬂammation
relevant feature given the defective interaction of the host
with the mucosal ﬂora in IBD. Macrophages isolated from
MTnull mice showed a signiﬁcantly lower bactericidal eﬀect
on Staphylococcus aureus than macrophages from control
mice. Furthermore, LPS- and TNF-α-stimulated MT-null
macrophages produced less NO than those from control
mice, which was due to reduced activity of inducible NO
synthase [73]. One MT isoform that was isolated and
puriﬁed from houseﬂy larvae had direct antibacterial eﬀects
on Escherichia coli as assayed by the plate growth inhibition
assay [74].
Under certain conditions such as cell proliferation,
diﬀerentiation, and after cell injury, MTs are translocated
from the cytosol to the nucleus. MT regulation during cell
cycle progression has been demonstrated in normally cycling
cells, with maximal nuclear accumulation within the S and
G2 phases. High cytoplasmic expression occurred during
late G1 and G1/S transition, and basal amounts were found
in the G0 phase [75, 76]. Hepatocytes show a transient
nuclear localization of MTs at the G1-to-S phase transition
during the priming phase of liver cell regeneration after
partial hepatectomy [77]. Two premises for the nuclear
retention of MTs have been proposed. First, it might reﬂect
the role of MTs as chaperones to provide zinc for crucial
enzymes and transcription factors involved in cell division
[78]. Otherwise, it has been proposed that it might protect
DNA from oxidative damage [79].
Beside their intracellular functions, MTs could also be
involved in inﬂammation and IBD through speciﬁc extra-
cellular eﬀects [80]. For example, MTs have been shown to
directly and speciﬁcally mediate leukocyte chemotaxis [81].
Extracellular MTs can stimulate lymphocyte proliferation
[82]. MT binds to the plasma membrane of both T and B
lymphocytes, but, in the absence of a costimulatory agent,
MT induces lymphoproliferation only in B cells. MT also
enhances the capacity of naive B lymphocytes to diﬀerentiate
into plasma cells [83]. On the other hand, MTs can suppress
cytotoxicTcellfunctioninvitroandaT-dependenthumoral
response in vivo [84–86].
4. MT ExpressioninIBD
Given their possible functions in IBD pathogenesis, the
expression of MTs has been studied in patient samples
by diﬀerent research groups. These studies have yielded
contradictory results (Table 1) and as such the role of
MTs in IBD is not yet clariﬁed. First of all, two studies
reported an increase in MT expression in IBD [87, 88], while
the rest demonstrated a downregulation. In most studies
no diﬀerences were reported between Crohn’s disease and
ulcerative colitis, except in two studies (both using DNA
microarrays) where opposite ﬁndings were found, that is,
decreased MT expression in ulcerative colitis and normal
expression in Crohn’s disease [89] versus normal expression
in ulcerative colitis and increased MT expression in Crohn’s
disease[88].Theinﬂuenceofmedicationisalsonotclearyet,
given that one study reports an inﬂuence of steroid therapy
on MT expression [90] whereas a second study contests this
[91]. A study describing downregulation of MTs in vitro in
colon epithelial cells after stimulation with azathioprine did
not discuss this eﬀectin patients, although two azathioprine-
treated patients were included in the study [88]. The results
of this study should be interpreted cautiously, considering
the small dataset used. Finally, the immunohistochemical
studies do not agree whether MT expression is conﬁned
to the epithelium [92–94] or whether expression in the
l a m i n ap r o p r i ao c c u r sa sw e l l[ 87, 90, 91]. The study of
MT protein expression in IBD is even complicated by the
possible destructive inﬂuence of the oxidative environment
on the immunodominant epitope of the protein. Therefore,
itisnotsurewhethertheabsenceofimmunoreactivityequals
absence of MT protein or whether it reﬂects a failure of the
antibody to recognize the present protein.
The inconsistencies between the various studies could
be explained by diﬀerent sampling. MT expression could
depend on the grade of local inﬂammation but also on
the intestinal region, that is, ileum versus colon. Therefore,
an ileal sample that has signs of mild inﬂammation and a
piece of colonic tissue that suﬀers severe inﬂammation, both
from a Crohn’s disease patient, may possibly show diﬀerent
MT expression levels, although they will both be considered
“Crohn’s disease” samples. Therefore, careful sampling and
precise classiﬁcation of the samples could help in elucidating
the exact MT expression pattern in IBD. Furthermore,
patient characteristics such as age, medication, disease activ-
ity, zinc status, or even food intake before sampling could
also inﬂuence MT levels and should therefore, if possible, be
examined or at least mentioned in the study outline.
5. MTs in ExperimentalColitis Models
The availability of MTnull mice (knockout for MT1 and
MT2) and the use of recombinant MT have permitted the
investigation of the involvement of MTs in animal models
of inﬂammation. In the DSS model of colitis, MTs were
not protective in two separate studies comparing MTnull
mice with wild type mice [44, 94]. One of these studies
even found that, after DSS administration, MTnull mice had
a signiﬁcantly lower disease activity index than had wild
type mice [44], suggesting that MTs are rather unfavorable
in DSS colitis. This ﬁnding was, however, not conﬁrmed
on histology. In disagreement with this postulation is the
observation that, in the same study, administration of zinc
as an MT-inducer resulted in a lower disease activity index
and less histological damage. Nevertheless, it could not be
proven that this eﬀect was MT-dependent since no increase
in colonic MT-levels was found following zinc-treatment.
The second study did not provide disease activity indices
and found no diﬀerences in histological colon damage
between MTnull mice, wild type mice, and transgenic mice
overexpressing MT1 in the intestine [94]. This study found a
fourfold increase in total colon MT concentration after seven
days of DSS administration, diﬀerent from other studies in
experimental colitis that found no changes [44]o rad e c r e a s e
in MT content [45] in DSS mice or in dinitrobenzene-
sulphonic acid colitic rats, respectively. Apparently, the
behaviourofMTsinexperimentalcolitismodelsisasobscure
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Table 1: MT expression in IBD patients. CD: Crohn’s disease, UC: ulcerative colitis, IHC: immunohistochemistry, RIA: radio-immunoassay,
Ag-hem: Silver-heme saturation assay, and qRT-PCR: quantitative reverse transcriptase-polymerase chain reaction.
Study Subjects Methods Results
Clarkson et al. [90]
Ileal resection specimens of 13 CD
patients (6 had received steroid
therapy; 5 had not), 2 UC patients,
and 3 controls
IHC on resection
specimens
Less MT immunoreactivity in patients with
IBD than controls; patients on steroid therapy
had more immunoreactivity;
immunoreactivity in enterocytes and lamina
propria
Elmes et al. [91]
Ileal resection specimens of 17 CD
patients (11 had received steroid
therapy; 6 had not), and 5 controls
IHC on resection
specimens
Decreased intestinal MT in IBD patients; no
signiﬁcant diﬀerence when patients had
received steroid therapy; immunoreactivity in
enterocytes and basement membrane region
Mulder et al. [95]
19 ileum and 16 colon specimens
from 29 CD patients; 12 colon
specimens and 1 ileum specimen
from 12 UC patients; colon
specimens from 18 control patients
RIA on homogenized
mucosa (dissected
from resection
specimens)
MT content was decreased in noninﬂamed IBD
mucosa compared with control mucosa;
further decrease, was found in inﬂamed
mucosa; no diﬀerences between UC and CD;
no signiﬁcant eﬀect of medication or tissue
localization
Sturniolo et al. [96] Colonic biopsies of 24 UC patients
and 10 controls Ag-hem on biopsies
Reduced MT concentrations in patients with
active disease as compared with controls and
patients in remission; reduced MT
concentrations in inﬂamed versus noninﬂamed
mucosa taken from the same patient
Bruwer et al. [87] 22 CD patients, 48 UC patients, 10
controls
IHC on resection
specimens
MT overexpression in the ﬁbroblasts of all
ulcerative and/or ﬁssural lesions in UC and
CD; MT overexpression in intestinal epithelial
cells of 40% of UC and CD lesions correlated
signiﬁcantly with the grade of inﬂammation
Lawrance et al. [89]
Colonic resection specimens with
moderately severe histological
inﬂammation from 12 UC and 6
CD patients (with moderately
severe clinical disease) and from 6
controls
DNA microarray Decrease of MT1H and MT1G mRNA
expression in UC; no diﬀerence in CD
Ioachim et al. [92]
Ileum, colon or rectum resection
specimens from 10 CD patients, 41
UC patients, 5 controls
IHC
Decreased MT expression in UC and CD
compared with normal mucosa; no diﬀerence
in MT expression between UC and CD; in UC,
a gradually decreased expression from
remission, to resolving and to active phase was
observed; only epithelial MT expression
Kruidenier et al. [93] Resection specimens from 19 CD
patients, 15 UC patients, 18 controls
RIA on tissue
homogenates and IHC
on resection specimens
RIA: Lower tissue MT content in inﬂamed CD
and UC mucosa compared with noninﬂamed
and control mucosa; IHC: decreased
MT-positive epithelial cell numbers at
inﬂamed sites in CD and UC patients; no
detection of MT in lamina propria
Dooley et al. [88]
2 sets of colon samples: (a) control
(1 uninvolved colon from CD
patient), 1 CD patient, and 1 UC
patient; (b) control, 1
azathioprine-treated CD patient,
and 1 azathioprine-treated UC
patient; drug-treated CaCo-2 cells
microarray and
qRT-PCR with
consensus primer
sequences for multiple
metallothionein genes.
Microarray: upregulation of MT1F, MT1G,
M T 1 Hi nC Di nt i s s u es e t( a ) ;d o w n r e g u l a t i o n
of MT1F, MT1H, MT1L in
azathioprine-treated CaCo-2 cells; conﬁrmed
by qRT-PCR
6.ProtectiveFunctionsofMTsin
Other AnimalModels of Inﬂammation
The role of MTs in models of other inﬂammatory conditions
seems clearer and in most cases is a favorable one. In an
animal model for multiple sclerosis, a chronic inﬂammatory
and demyelinating disease of the central nervous system in
which oxidative stress plays a pathogenic role, MTs were
demonstrated to be protective [97]. MTnull mice were
more susceptible to Helicobacter pylori-induced gastritis and6 Mediators of Inﬂammation
showed more severe inﬂammation of the stomach than wild
typemice[98].Thiscorrelateswiththereportedantibacterial
activity that was associated with MT function. This activity
might be mediated directly by MTs themselves [74]o r
indirectly through nitric oxide production [73]. Endogenous
MT protected against acute lung injury induced by LPS,
especially against pulmonary oedema [56]. In the collagen-
induced arthritis model, repeated administration of MT1
and 2 during the course of disease dramatically reduced the
incidence and severity of the disease [99]. MTs suppressed
the disease through the generation of IL-10- and transform-
ing growth factor (TGF)-β-producing type 1 regulatory T-
like cells [100]. In all of these models, MTs seem to be
protective against local inﬂammation. In the TNF-induced
lethal shock model (a model for systemic inﬂammatory
response syndrome), however, MTs seem to sensitize [101].
An explanation for this ﬁnding was not found, although it
is contradictory to the reported resistance that MTs confer
to the cytotoxic eﬀects of TNF in vitro [102] and to the
protective eﬀects of MTs in another model of systemic
inﬂammatory response syndrome (LPS-induced lethal shock
in sensitized mice) [103]. The antiinﬂammatory eﬀects of
MTs on the LPS-related organ damages could be mediated,
at least in part, via the inhibition of the protein expression
of proinﬂammatory cytokines (IL-1β, IL-6) and chemokines
(granulocyte/macrophage colony-stimulating factor (GM-
CSF), macrophage inﬂammatory protein (MIP)-1α,M I P -
2, macrophage chemoattractant protein (MCP)-1, and ker-
atinocyte chemoattractant (KC)) [104].
7. Conclusion
Although several functional associations of MTs can confer
a role for this family of proteins in the pathogenesis of
IBD, the results of human and experimental colitis studies
a r en o td e c i s i v e .H o w e v e r ,i ti sc l e a rt h a tad e v i a n tM T
expression exists in this disease, and as such it is important
to meticulously clarify these aberrations in Crohn’s disease
and in ulcerative colitis. Furthermore, investigating whether
the regulation of MTs in these diseases is dependent or
independent on inﬂammation will add knowledge on their
involvement in IBD.
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